ArticleClinical and translational radiation oncology2026
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancer.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/objectives: Metastasis directed therapy (MDT) with stereotactic body radiotherapy (SBRT) has demonstrated clinical benefit among select oligometastatic prostate cancer (PCa) patients. The outcomes of SBRT to the left supraclavicular lymph nodes (SCLNs) are examined. Materials/methods: Between 2017 and 2024, 16 (3.8%) of 419 patients with PCa metastatic to lymph nodes were found by prostate-specific PET to have SCLN involvement. Survival, relapse patterns, and toxicity are analyzed. Results: At initial PCa diagnosis, median PSA was 6.7 ng/mL (range 2.1-315) with 50% of patients having Gleason score of 8-10. Mean time from initial diagnosis to SCLN metastasis was 10.4 years with median PSA of 2.0 ng/mL and median number of involved SCLNs of 1.5 (range 1-10). The most common fractionation scheme was 35 Gy in 5 fractions daily (44%) with 81% of patients receiving concurrent hormonal therapy. No grade ≥ 2 toxicities were reported. Local relapse-free survival at 5 years was 90.9%. Mean distant progression-free survival was 16.7 months (95% CI: 7.9-25.5). Mean prostate cancer-specific survival (PCSS) and overall survival were 4.6 years (95% CI: 3.6-5.6) and 4.0 years (95% CI: 2.8-5.1), respectively. Patients with castration-sensitive disease had 100% 5-year PCSS, and 58.3% for those with mCRPC. Conclusion: SBRT to SCLNs was well tolerated with no significant toxicity. Durable local control was satisfactory. The presence of SCLN metastases is frequently a harbinger of additional metastatic progression which suggests that patients require close monitoring and could benefit from the addition or intensification of systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.